Disparities in Drug Access between Japan and the United States for Designated Intractable Diseases: A Cross-Sectional Analysis of Approval Status, Prevalence, and Drug Lag
This cross-sectional analysis reveals that approximately 70% of designated intractable diseases in Japan and the US lack approved pharmacological treatments in either country, with significant unmet needs in ultra-rare and nervous system disorders, while substantial drug lags persist even for conditions where therapies are available in both nations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine a world where a person's illness is so rare that it barely registers on the map of global medicine. In Japan, these conditions are officially recognized as designated intractable diseases, a category reserved for ailments that are difficult to treat and often lack effective cures. For decades, the country has maintained a system to support research into these rare ailments, offering financial incentives to encourage scientists to develop new medicines. Yet, a persistent shadow looms over this effort: the time it takes for a medicine to become available in Japan after it has already been approved elsewhere. This delay, known as drug lag, means patients wait longer for relief. Even more troubling is the possibility of drug loss, where a medicine is developed and approved in other countries but never even submitted for approval in Japan, leaving patients with no access at all. While these issues have been discussed broadly, the specific landscape of how these rare diseases are treated across two major medical powers has remained largely uncharted.
A team of researchers from Meiji Pharmaceutical University set out to map this territory with precision. They focused on the 341 diseases currently designated as intractable in Japan. Because some of these broad categories contain many distinct conditions, the researchers broke them down into 368 specific diseases to get a clear picture. They then compared the status of these diseases in Japan against the United States, checking two massive public databases to see which medicines had been formally approved for each condition. They did not count medicines used off-label or those that merely treated symptoms; they looked only for drugs specifically approved to treat the disease itself. They also examined how common each disease was in Japan and how long it took for a drug to appear in Japan after its first approval in the US.
The results revealed a stark reality. Of the 368 diseases analyzed, nearly 70 percent had no approved drug in either Japan or the United States. This means that for the vast majority of these rare conditions, patients in both nations are left without a specific pharmacological treatment. The researchers found that the gap between the two countries was not a one-sided story where one nation consistently led the other. The number of diseases with a drug approved only in Japan was almost identical to the number with a drug approved only in the US. This suggests that the lack of treatment is a global challenge rather than a failure of a single country's system. However, the data showed a clear pattern related to how many people suffer from a disease. The rarer the condition, the less likely it was to have a treatment. Among diseases affecting fewer than one person in every 100,000, more than 80 percent had no approved drug in either country. As the number of patients increased, the likelihood of having a treatment rose, but the most common diseases still did not guarantee a cure.
The study also highlighted which types of diseases were suffering the most. Conditions affecting the nervous system and those involving congenital malformations or chromosomal abnormalities were the most underserved. These two groups alone accounted for more than half of all the diseases that lacked treatment in both nations. The researchers noted that the extreme variety within these groups and the difficulty of delivering drugs to the brain or correcting genetic errors likely contribute to this lack of progress. Conversely, diseases affecting the skin or the urinary system had much higher rates of available treatments, possibly because existing medicines could be adapted more easily for these conditions.
Even when a drug was available in both countries, the timing of its arrival told a different story. For diseases in the endocrine, nutritional, and metabolic categories, there was often a significant delay before a drug became available in Japan. In some cases, this lag stretched for several years, with a few specific conditions waiting decades for their first approved therapy. This suggests that even when a path to treatment exists, the journey to get that medicine to Japanese patients remains long and difficult. The researchers concluded that while Japan has made strides in its regulatory review times, the fundamental barriers of small patient populations and complex disease mechanisms remain. To bridge the gap, they suggest that future efforts must focus on helping researchers reach patients across multiple countries simultaneously, building better records of patient data, and exploring new types of therapies that might work where traditional drugs have failed. The goal is to ensure that the rarity of a disease does not dictate the absence of hope.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.